NCT02248571 - Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

September 30, 2017

Conditions

Breast Cancer RecurrentHER2/Neu-negative Carcinoma of BreastHormone Receptor Positive Malignant Neoplasm of Breast

Interventions

DRUG

Bevacizumab

administered as combined therapy with Capecitabine

DRUG

Capecitabine

administered as combined therapy with Bevacizumab

DRUG

Everolimus

administered as combined therapy with Exemestane

DRUG

Exemestane

administered as combined therapy with Everolimus

OTHER

Patient questionaires

Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference

Trial Locations (1)

iOMEDICO AG, Freiburg im Breisgau